Clinical Focus

  • Anatomic and Clinical Pathology

Academic Appointments

Administrative Appointments

  • Vice Chair of Pathology for Pediatric Pathology, Stanford University School of Medicine (2015 - Present)
  • Associate Medical Director of Pathology and Clinical Laboratories for Pediatrics, Stanford Children's Health/Stanford Health Care (2014 - Present)
  • Chief of Pathology, Lucile Packard Children’s Hospital, Stanford Children’s Health (2014 - Present)
  • Director of Pediatric Pathology, Stanford University Medical Center (2014 - Present)
  • Vice-Chairman for Anatomical Pathology, Medical College of Wisconsin, Milwaukee, WI (2012 - 2014)
  • Director of Anatomical and Surgical Pathology, Medical College of Wisconsin, Milwaukee, WI (2010 - 2014)
  • Director of Orthopedic Pathology, Yale University School of Medicine, New Haven, CT (2008 - 2009)
  • Director of Pediatric and Developmental Pathology, Yale University School of Medicine, New Haven, CT (2008 - 2009)
  • Assistant Director of Autopsy Services, Yale University School of Medicine, New Haven, CT (2007 - 2009)

Professional Education

  • Board Certification: Anatomic and Clinical Pathology, American Board of Pathology (2003)
  • Board Certification: Pediatric Pathology, American Board of Pathology (2003)
  • Board certification, Children's Hospital Boston/Harvard Medical School, Pediatric Pathology (2003)
  • Board certification, Yale-New Haven Hospital/Yale School of Medicine, Anatomical and Clinical Pathology (2002)
  • Residency:Yale-New Haven HospitalCT
  • Professional Certificate, University of New Haven, Health Care Management (2001)
  • Medical Education:Universidad Catolica de Santiago de Guayaquil (1992) Ecuador
  • MSc, Vrije Universiteit Brussel, Brussels, Belgium, Molecular Biology (1994)
  • Fellowship:Children's Hospital BostonMA
  • MD, Universidad Católica de Santiago de Guayaquil, Ecuador, Medicine and Surgery (1992)

Research & Scholarship

Clinical Trials

  • Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-Rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Recruiting

    This randomized phase II/III trial studies how well pazopanib hydrochloride, combination chemotherapy, and radiation therapy work and compares it to radiation therapy alone or in combination with pazopanib hydrochloride or combination chemotherapy in treating patients with newly diagnosed non-rhabdomyosarcoma soft tissue sarcomas that can be removed by surgery. Radiation therapy uses high energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as ifosfamide and doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether radiation therapy works better when given with or without combination chemotherapy and/or pazopanib hydrochloride in treating patients with non-rhabdomyosarcoma soft tissue sarcomas.

    View full details


2016-17 Courses


All Publications

  • First case of infectious endocarditis caused by Parvimonas micra ANAEROBE Gomez, C. A., Gerber, D. A., Zambrano, E., Banaei, N., Deresinski, S., Blackburn, B. G. 2015; 36: 53-55


    P. micra is an anaerobic Gram-positive cocci, and a known commensal organism of the human oral cavity and gastrointestinal tract. Although it has been classically described in association with endodontic disease and peritonsillar infection, recent reports have highlighted the role of P. micra as the primary pathogen in the setting of invasive infections. In its most recent taxonomic classification, P. micra has never been reported causing infectious endocarditis in humans. Here, we describe a 71 year-old man who developed severe native valve endocarditis complicated by aortic valvular destruction and perivalvular abscess, requiring emergent surgical intervention. Molecular sequencing enabled identification of P. micra.

    View details for DOI 10.1016/j.anaerobe.2015.10.007

    View details for Web of Science ID 000367027400009

  • Sarcoma Resection With and Without Vascular Reconstruction: A Matched Case-control Study ANNALS OF SURGERY Poultsides, G. A., Tran, T. B., Zambrano, E., Janson, L., Mohler, D. G., Mell, M. W., Avedian, R. S., Visser, B. C., Lee, J. T., Ganjoo, K., Harris, E. J., Norton, J. A. 2015; 262 (4): 632-640


    To examine the impact of major vascular resection on sarcoma resection outcomes.En bloc resection and reconstruction of involved vessels is being increasingly performed during sarcoma surgery; however, the perioperative and oncologic outcomes of this strategy are not well described.Patients undergoing sarcoma resection with (VASC) and without (NO-VASC) vascular reconstruction were 1:2 matched on anatomic site, histology, grade, size, synchronous metastasis, and primary (vs. repeat) resection. R2 resections were excluded. Endpoints included perioperative morbidity, mortality, local recurrence, and survival.From 2000 to 2014, 50 sarcoma patients underwent VASC resection. These were matched with 100 NO-VASC patients having similar clinicopathologic characteristics. The rates of any complication (74% vs. 44%, P = 0.002), grade 3 or higher complication (38% vs. 18%, P = 0.024), and transfusion (66% vs. 33%, P < 0.001) were all more common in the VASC group. Thirty-day (2% vs. 0%, P = 0.30) or 90-day mortality (6% vs. 2%, P = 0.24) were not significantly higher. Local recurrence (5-year, 51% vs. 54%, P = 0.11) and overall survival after resection (5-year, 59% vs. 53%, P = 0.67) were similar between the 2 groups. Within the VASC group, overall survival was not affected by the type of vessel involved (artery vs. vein) or the presence of histology-proven vessel wall invasion.Vascular resection and reconstruction during sarcoma resection significantly increases perioperative morbidity and requires meticulous preoperative multidisciplinary planning. However, the oncologic outcome appears equivalent to cases without major vascular involvement. The anticipated need for vascular resection and reconstruction should not be a contraindication to sarcoma resection.

    View details for DOI 10.1097/SLA.0000000000001455

    View details for Web of Science ID 000367999800009